Company:  GERON CORP (GERN)
Form Type:  10-Q
Filing Date:  11/6/2019 
CIK:  0000886744 
Address:  919 EAST HILLSDALE BOULEVARD
SUITE 250
 
City, State, Zip:  FOSTER CITY, California 94404 
Telephone:  (650) 473-7700 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$1.54  
Change: 
0.00 (0.00%)  
Trade Time: 
Jun 05  
Market Cap: 
$477.96M
Trade GERN now with 

© 2020  
Description of Business
We are a late-stage clinical biopharmaceutical company that is focused on the development and potential commercialization of imetelstat, an innovative therapeutic for hematologic myeloid malignancies. We have global rights to imetelstat, a first-in-class telomerase inhibitor, which was discovered and developed at Geron. We believe targeting telomerase has the potential to inhibit the uncontrolled proliferation of malignant progenitor cells in hematologic myeloid malignancies to reduce dysfunctional blood cell production and enable recovery of normal blood cell production. Data reported from our Phase 2/3 clinical trial in lower risk myelodysplastic syndromes, or MDS, indicate imetelstat may induce meaningful and durable transfusion independence and increases in hemoglobin levels, suggesting potential recovery of normal blood cells occurring in the bone marrow, or hematopoiesis.
Register and access this filing in:     
  FORM 10-Q
    PART I. FINANCIAL INFORMATION
      ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)
        BALANCE SHEET
        INCOME STATEMENT
        STOCKHOLDERS EQUITY
        STOCKHOLDERS EQUITY
        CASH FLOW
        NOTES TO CONDENSED FINANCIAL STATEMENTS
      ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL ...
      ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT ...
      ITEM 4. CONTROLS AND PROCEDURES
    PART II. OTHER INFORMATION
      ITEM 1. LEGAL PROCEEDINGS
      ITEM 1A. RISK FACTORS
      ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF ...
      ITEM 3. DEFAULTS UPON SENIOR SECURITIES
      ITEM 4. MINE SAFETY DISCLOSURES
      ITEM 5. OTHER INFORMATION
      ITEM 6.EXHIBITS
    SIGNATURES
  EXHIBIT 10.1
  EXHIBIT 31.1
    CERTIFICATION PURSUANT TO
  EXHIBIT 31.2
    CERTIFICATION PURSUANT TO
  EXHIBIT 32.1
    CERTIFICATION PURSUANT TO
  EXHIBIT 32.2
    CERTIFICATION PURSUANT TO